Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Acquired by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. lifted its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 15.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 845,154 shares of the company's stock after purchasing an additional 112,221 shares during the period. Vestmark Advisory Solutions Inc. owned about 0.22% of Recursion Pharmaceuticals worth $5,713,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its position in shares of Recursion Pharmaceuticals by 17.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company's stock worth $12,789,000 after purchasing an additional 288,926 shares during the last quarter. Accel Wealth Management purchased a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth $310,000. FMR LLC lifted its position in shares of Recursion Pharmaceuticals by 2.1% during the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company's stock worth $55,116,000 after purchasing an additional 170,810 shares during the last quarter. Avanza Fonder AB purchased a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth $580,000. Finally, State Street Corp lifted its position in shares of Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock worth $84,815,000 after purchasing an additional 4,120,685 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ:RXRX traded up $0.35 on Friday, reaching $6.59. The company's stock had a trading volume of 19,150,247 shares, compared to its average volume of 25,833,668. The stock's 50-day moving average is $7.64 and its two-hundred day moving average is $7.07. Recursion Pharmaceuticals, Inc. has a 52-week low of $5.60 and a 52-week high of $12.36. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The stock has a market capitalization of $2.57 billion, a P/E ratio of -4.31 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $4.60 million during the quarter, compared to analysts' expectations of $19.04 million. During the same period in the previous year, the company posted ($0.42) earnings per share. Recursion Pharmaceuticals's quarterly revenue was down 57.8% on a year-over-year basis. As a group, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on RXRX. Leerink Partners reduced their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Needham & Company LLC reissued a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. KeyCorp reduced their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Finally, Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of "Hold" and an average price target of $8.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.